

Rakovina Therapeutics to Present Abstract at the 2022 AACR Special Conference – Sarcomas

Company will highlight new data with kt-3000 lead candidates as a potential treatment for Ewing sarcoma

VANCOUVER, BC, March 30, 2022 /CNW/ – Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies, is pleased to announce the acceptance of an abstract to be presented at the 2022 AACR Special Conference on Sarcomas. The conference is being held May 9-12, 2022 in Montreal, Canada.

Rakovina Therapeutics’ presentation entitled *In vitro efficacy of a novel dual PARP-HDAC Inhibitor in Ewing sarcoma* will highlight the Company’s development of its novel kt-3000 series drug candidates as a potential treatment of sarcomas and soft tissue tumors.

Sarcomas are a rare but complex group of malignant tumors that affect 1% of the adult population but are more prevalent among children, representing about 15% of pediatric cancers. The conference will provide a forum for critically reviewing the evidence of the role of biological mechanisms in the cause and progression of sarcomas, in addition to examining the current and novel therapies available for combating this cancer.

Rakovina Therapeutics kt-3000 series represents a novel class of small-molecule bi-functional drug candidates that exhibit potent inhibition of both poly (ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC). The Company has previously presented preclinical data at peer reviewed scientific meetings demonstrating the potential of kt-3000 series drug candidates against treatment-resistant cancer cell lines. The development of the kt-3000 series is supported, in part, by the [St. Baldrick’s Foundation](#) Martha’s BEST Grant for All, which is aimed at developing new treatments for Ewing sarcoma, an aggressive bone and soft tissue cancer in children and young adults.

Further information regarding the conference, including registration details, can be found at: <https://www.aacr.org/meeting/sarcomas/>

About Rakovina Therapeutics Inc.

Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response (DDR) technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com

Additional Information

The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Notice regarding forward-looking statements:

This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company’s most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at www.sedar.com.

Contact:

Rakovina Therapeutics Inc.

David Hyman

Chief Financial Officer

Email: info@rakovinatherapeutics.com

Investor Relations Contact

IR@rakovinatherapeutics.com

Media Contact

MEDIA@rakovinatherapeutics.com